CURX FY 2022 Earnings Report — Curanex Pharmaceuticals Inc Common Stock Revenue & Financial Results | Market Cap Arena

Curanex Pharmaceuticals Inc Common StockCURX

FY 2022 Earnings

Reported December 31, 2022

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Metric	FY 2022	Prior Q	FY 2021	QoQ Change	YoY Change
Revenue	$26.0K	—	—	—	—
Op. Income	-$20.2K	—	—	—	—
Gross Margin	17.0%	—	—	—	—
Net Margin	-77.8%	—	—	—	—
EPS (Diluted)	$-0.02	—	—	—	—

Income Statement

Item	Amount
REVENUE	$26.0K
Cost of Revenue	$21.6K
GROSS PROFIT	$4.4K
R&D Expenses	$0
Selling & Marketing	$0
General & Administrative	$24.7K
SG&A Expenses	$24.7K
Other Expenses	$0
Operating Expenses	$24.7K
Cost & Expenses	$46.2K
OPERATING INCOME	-$20.2K
Interest Income	$0
Interest Expense	$0
Other Income/Expenses	$0
INCOME BEFORE TAX	-$20.2K
Income Tax Expense	$0
Net Income from Continuing Ops	-$20.2K
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	-$20.2K
Net Income Deductions	$0
BOTTOM LINE NET INCOME	-$20.2K
D&A	$21.2K
EBIT	-$20.2K
EBITDA	$925
EPS	-$0
EPS Diluted	-$0